Jason has held leading roles building consulting, pharma and technology companies over the last 20 years including Indivior PLC, which exited in a £2.5B listing (LSE: INDV) in December 2014. Ori Biotech’s mission is to making cell and gene therapy commercially viable, in large part through innovations in manufacturing.